Clinical Research Directory
Browse clinical research sites, groups, and studies.
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
Summary
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.
Official title: A Phase II Study to Evaluate the Safety and Efficacy of SSGJ-705 Monotherapy and Combination Therapy in Patients With Advanced HER2-Expressing Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
340
Start Date
2025-07-30
Completion Date
2027-12-12
Last Updated
2025-08-03
Healthy Volunteers
No
Interventions
SSGJ-705
anti-PD-1 (programmed cell death protein 1) and anti-HER2 (Human Epidermal GrowthFactor Receptor 2)bispecifc antibody
PD-1/L1 inhibitor combined with chemotherapy
Immune checkpoint inhibitors
SSGJ-705 combined with chemotherapy
anti-PD-1 and anti-HER2 bispecifc antibody
Locations (1)
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China